Neuland Laboratories Limited has informed the Exchange regarding 42nd Annual General Meeting Of The Shareholders Of The Company Is Scheduled To Be Held On Tuesday, August 4, 2026'.
NEULANDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Neuland Laboratories reported strong FY2026 results with consolidated revenue growing 37% to ₹2,02,299 lakhs from ₹1,47,684 lakhs in FY2025. Profit after tax rose 40% to ₹36,400 lakhs from ₹26,011 lakhs, driven by robust growth across all geographies — Europe revenue up 57% and USA/North America up 69%. EBITDA margin expanded from ~18% to ~24%. The company recorded an exceptional gain of ₹7,640 lakhs from sale of investment property in Hyderabad. Board recommended final dividend of ₹34 per share (340%). New director Dr. Mauricio Futran appointed. The company approved ₹143.4 crore capacity expansion at Unit 1 (adding 120.5 KL over 12-18 months) citing 91% capacity utilization. Auditors issued unmodified (clean) opinion.
Strong growth trajectory with margin expansion signals operational efficiency gains. The one-time exceptional item boosted bottom line; underlying business shows robust organic growth. Capacity expansion indicates confidence in sustained demand, particularly from US and Europe markets.